Divya Sharma | Signal Transduction Mechanisms | Best Researcher Award

Published on by Cell Biologist

Dr. Divya Sharma | Signal Transduction Mechanisms | Best Researcher Award

Amity University, Punjab | India

Dr. Divya Sharma is an accomplished researcher and academic in Computer Science and Engineering, specializing in information security, cyber vulnerabilities, and electronic medical image protection. She completed her B.Tech. in CSE from Shaheed Udham Singh College of Engineering & Technology, Mohali, followed by an M.Tech. in CSE from Rayat & Bahra Institute of Engineering & Biotechnology, Kharar, and earned her Ph.D. from Chitkara University in 2025 with a CGPA of 9.15. Over her career, she has contributed significantly to the field of cybersecurity, publishing research on electronic medical image security and hybrid edge-based steganography with three-layered cryptography, presented at conferences including ICOECA-2024, CUDC-2023, and ADSSS-2023. She has actively engaged in faculty development, attending programs on cyber vulnerabilities, emerging engineering trends, and ICT-based classroom communication. Currently, she serves as an Assistant Professor in the Department of Information Technology at Panjab University SSG Regional Center, Hoshiarpur. Dr. Sharma’s work has been recognized for its impact, with multiple papers cited in peer-reviewed venues, reflecting her growing scholarly influence. She has also participated in numerous short-term courses and industry training programs, enhancing her expertise in relational databases, VB.NET, and applied data science, contributing to both teaching excellence and research innovation.

Profiles: Google Scholar | Orcid

Featured Publications:

Sharma, D. (2024, April 18–19). Electronic medical images security and privacy techniques. In 4th International Conference on Expert Clouds and Applications (ICOECA-2024), RV College of Engineering, Bengaluru, India.

Sharma, D. (2024). Hybrid security of EMI using edge-based steganography and three-layered cryptography. In Applied Data Science and Smart Systems (pp. 278–290). CRC Press.

Sharma, D., & Prabha, C. (2023, May 5–6). Security and privacy aspects of electronic health records: A review. In 2023 International Conference on Advancement in Computation & Computer Technologies (ICACCT). IEEE.

Sharma, D., & Kawatra, R. (2022, July 29–30). Security techniques implementation on big data using steganography and cryptography. In ICT Analysis and Applications (pp. 279–302). Springer Nature Singapore.

Sharma, D. (2015, Sept 4–5). Implementing chi-square method and even mirroring for cryptography of speech signal using MATLAB. In 1st International Conference on Next Generation Computing Technologies (NGCT-2015) (pp. 394–397). IEEE.

Sharma, D. (2015, Dec 21–22). Steganography of speech signal into an image. In 2nd International Conference on Recent Advances in Engineering and Computational Sciences (RAECS-2015) (pp. 1–4). IEEE.

Kudiyarasan Swamynathan | Signal Transduction Networks | Best Industrial Research Award

Published on by Cell Biologist

Dr. Kudiyarasan Swamynathan | Signal Transduction Networks | Best Industrial Research Award

NLCIL | India

Dr. S. Kudiyarasan is a distinguished electrical engineer and renewable energy expert serving as the Deputy General Manager (Electrical – Renewable Energy) at NLC India Limited, a Navratna Public Sector Enterprise in Neyveli, Tamil Nadu. With a career spanning over two decades, he has significantly contributed to the development and implementation of solar and wind power projects across India. His academic journey commenced with a First Class with Honours in SSLC from Pachaiyappas Higher Secondary School, Kanchipuram, followed by a Diploma in Electrical and Electronics Engineering from Bhaktavatsalam Polytechnic College, Kanchipuram. Dr. Kudiyarasan further advanced his expertise with a Ph.D., and is a Fellow and Chartered Engineer certified by The Institution of Engineers (India). He has authored 27 peer-reviewed publications, amassing over 7,240 reads and 48 citations on ResearchGate. His research interests encompass power electronics, control systems, and renewable energy technologies. Dr. Kudiyarasan’s work has been recognized with accolades such as GATE scores of 90.45 percentile and 85.99 percentile. He is also an active member of professional bodies, including the Institution of Engineers (India), contributing to advancements in electrical engineering and renewable energy sectors.

Profiles: Scopus | Orcid

Featured Publications:

Swamynathan, K., Sasi, G., Selvakumarasamy, K., Kamatchi, S., Vijayalakshmi Sankaran, & Alagumariappan, P. (2025). Improved Bat Algorithm for security level enhancement in multi-domain communication network model. Journal of The Institution of Engineers (India): Series B. Springer.

Kamatchi, S., Swamynathan, K., Jayashankar, H., Vijayalakshmi, S., & Paramasivam, A. (2024). Empirical wavelet transform using MUSIC algorithm for near-infrared evaluation of sinusitis. Journal of The Institution of Engineers (India): Series B. Springer Science and Business Media LLC.

Premalatha, P., Shilpa, N., Vijayalakshmi Sankaran, Paramasivam, A., Pittu, P. S. K. R., Kamatchi, S., Jayashankar, H., & Swamynathan, K. (2024). A novel method for detecting cardiac arrhythmias in electrocardiogram signals using the ANFIS classifier. e-Prime – Advances in Electrical Engineering, Electronics and Energy, 9, 100734.

Vijayalakshmi, S., Paramasivam, A., Velmurugan, N., Swamynathan, K., Kamatchi, S., & Jayashankar, H. (2024). Design and performance analysis of Manchester coder based body channel communication using FPGA. e-Prime – Advances in Electrical Engineering, Electronics and Energy, 9, 100660.

Biswas, S. S., & Swamynathan, K. (2024). Optimization of overall heat transfer coefficient of fin tube assembly of frozen seal valve using CFD analysis. SAE International Journal of Materials and Manufacturing, 17(4).

Kai Zhao | Signal Transduction Mechanisms | Cell Biology Research Award

Published on by Cell Biologist

Dr. Kai Zhao | Signal Transduction Mechanisms | Cell Biology Research Award

Dr. Kai Zhao | shandong first medical university | China

Kai Zhao is a dedicated biomedical scientist specializing in cell biology and translational medical research. Affiliated with the Central Hospital and Shandong First Medical University, Kai has focused on molecular mechanisms underlying diseases such as osteosarcoma and neurodegeneration. Their expertise includes mitophagy regulation, exosomal gene biomarkers, and multi-omics analyses, aiming to discover novel therapeutic targets. Kai has contributed significantly to understanding how cellular degradation pathways influence disease progression, with published work in prominent journals. They hold key roles in both clinical and research settings, bridging basic science and patient care. Their collaborative work and innovative approach have garnered attention in the biomedical community, underscoring their role as a rising leader in cell biology research.

Publication Profile: 

Orcid

Education:

Kai Zhao completed their foundational studies in medicine at a prestigious medical university in China, followed by advanced graduate training focusing on cellular and molecular biology. Their education provided a strong grounding in clinical medicine combined with rigorous laboratory research skills. They further specialized through postgraduate work that integrated molecular biology techniques and omics technologies, developing expertise in the mechanisms of disease at a cellular level. This multidisciplinary education enabled Kai to pursue research at the interface of clinical practice and experimental biology. They have also completed specialized training in bone biomechanics and metabolism, as well as spinal surgery, enhancing their ability to conduct translational research. Continuous professional development through workshops, conferences, and collaborative projects complements their formal education, keeping them updated on cutting-edge scientific advances.

Experience:

Kai Zhao has extensive experience working at the Central Hospital Affiliated with Shandong First Medical University, where they contribute both clinically and in research. Their experience includes investigating molecular pathways in osteosarcoma and neurodegenerative models using cell lines such as SH-SY5Y. Kai has led projects applying multi-omics data to identify exosomal gene biomarkers and therapeutic targets like mifepristone. Their role in the Spinal Surgery Department and Bone Biomechanics Laboratory has provided hands-on clinical insight, informing their research on bone and spinal disorders. Kai collaborates with multidisciplinary teams, combining clinical knowledge with molecular techniques. Their publication record reflects proficiency in advanced methodologies such as mitophagy analysis, molecular degradation pathways, and biomarker discovery. Kai also mentors junior researchers and participates in academic dissemination through publications and conferences, demonstrating leadership and a commitment to advancing cell biology research.

Research Focus:

Kai Zhao’s research centers on the molecular and cellular mechanisms driving disease, with an emphasis on mitophagy, exosomal biomarkers, and multi-omics analyses. They investigate how cellular quality control systems, such as the PINK1-mediated mitophagy pathway, contribute to neurodegenerative diseases and cancer progression, specifically osteosarcoma. By combining genomic, proteomic, and transcriptomic data, Kai aims to identify novel gene biomarkers within exosomes that can serve as diagnostic or therapeutic targets. One highlighted therapeutic candidate from their work is mifepristone, revealed through integrative multi-omics to be effective against osteosarcoma. Their research integrates cellular biology with clinical insights, particularly in bone metabolism and spinal diseases, aiming for translational impact. Overall, Kai’s focus is on uncovering how disruptions in cellular degradation and intercellular communication contribute to disease, leveraging multi-disciplinary approaches to develop targeted therapies.

Publication Top Notes:

    • Exosomal Gene Biomarkers in Osteosarcoma: Mifepristone as a Targeted Therapeutic Revealed by Multi‐Omics Analysis

    • IRGM promotes the PINK1-mediated mitophagy through the degradation of Mitofilin in SH-SY5Y cells

Conclusion:

Kai Zhao is a promising and capable researcher whose work directly contributes to cutting-edge cell biology, particularly in disease mechanisms. Their multi-omics and cellular degradation studies mark them as an excellent candidate for the Cell Biology Research Award.

Yanhua Liang | Signal Transduction Mechanisms | Best Researcher Award

Published on by Cell Biologist

Prof. Yanhua Liang | Signal Transduction Mechanisms | Best Researcher Award

Prof. Yanhua Liang, Shenzhen Hospital of Southern Medical University, China

Dr. Yan-Hua Liang,  is a distinguished dermatologist, academic, and researcher. He serves as Chairman and Chief Physician in the Department of Dermatology at Shenzhen Hospital, Southern Medical University. With over two decades of clinical and research experience, he is widely recognized for his contributions to dermatological science and translational medicine. Dr. Liang holds dual PhDs and has trained internationally, including a postdoctoral fellowship at The Jackson Laboratory in the U.S. His commitment to advancing psoriasis therapy, dermatological immunology, and healthcare system improvements is evident in his prolific publication record and mentorship roles. He actively collaborates with global experts and consistently publishes in high-impact journals. Through a career grounded in clinical excellence and research innovation, Dr. Liang continues to shape the field of dermatology in China and beyond.\

Publication Profile: 

Scopus

Strengths for the Award

  1. Proven Academic Excellence

    • Holds M.D., dual Ph.D.s, and completed a prestigious postdoctoral fellowship at The Jackson Laboratory, USA — reflecting strong scientific and international credentials.

  2. Clinical Leadership & Longstanding Experience

    • Over 20 years in dermatology, currently serving as Chairman and Chief Physician at a major university-affiliated hospital.

  3. Research Output & Innovation

    • 10+ high-quality peer-reviewed publications (2023–2025) in leading journals like Scientific Reports, Drug Safety, Frontiers in Medicine, and Dermatology.

    • Focus on real-world studies, biologic therapies, psoriasis, autoimmune skin diseases, and translational dermatology — addressing clinically relevant problems.

  4. Mentorship and Academic Contributions

    • Active Ph.D. supervisor, guiding the next generation of dermatological researchers.

    • Collaborates with both domestic and international institutions, boosting China’s contribution to global dermatology research.

  5. Multidisciplinary Impact & Public Health Relevance

    • Involved in infectious disease preparedness (Monkeypox) and healthcare system education for medical professionals.

Areas for Improvement

  1. International Visibility & Awards

    • While the academic record is strong, international keynote roles, global society leadership, or major global awards are not yet highlighted. These would further elevate his candidacy.

  2. Broader Interdisciplinary Integration

    • Could explore collaborative work in AI-driven dermatology, digital diagnostics, or bioinformatics, which are emerging fields in skin science.

Education (150 words)

Dr. Liang’s academic journey reflects a steadfast pursuit of medical excellence. He earned his Bachelor of Medicine from Gannan Medical University (1996–2001), followed by a Master of Science and Ph.D. in Dermatology from Anhui Medical University (2001–2007). To further enrich his scientific acumen, he completed a Postdoctoral Fellowship at The Jackson Laboratory, USA (2007–2010), a premier institution for biomedical research. His education combines strong clinical training with rigorous research methodology, particularly in genetics and dermatological sciences. Dr. Liang’s dual PhDs signify his interdisciplinary focus and commitment to integrating basic science into clinical innovation. His international training has enabled him to bridge Eastern and Western medical practices and adopt a global perspective in addressing skin diseases. With a strong foundation in immunodermatology, translational medicine, and evidence-based treatments, Dr. Liang’s academic background is a cornerstone of his success as a clinician-scientist and mentor.

Experience (150 words)

Dr. Yan-Hua Liang has over 20 years of experience in clinical dermatology and academic leadership. He currently holds the title of Chairman and Professor at the Department of Dermatology, Shenzhen Hospital, Southern Medical University (since 2016). Prior to this, he was a Professor at Nanfang Hospital, also part of Southern Medical University (2012–2015). His clinical expertise spans psoriasis, atopic dermatitis, and autoimmune skin diseases, with a focus on biologic therapies and translational dermatology. He has treated thousands of patients and led major clinical trials in China. As a Ph.D. supervisor, Dr. Liang has mentored numerous postgraduate students and emerging researchers. His leadership has helped modernize dermatological practices, elevate research standards, and foster international collaborations. Recognized for his medical innovations and deep patient care, Dr. Liang stands out as a thought leader in dermatology in the Greater Bay Area and nationally.

Research Focus (150 words)

Dr. Liang’s primary research interests lie in psoriasis treatment, immunodermatology, and translational skin research. He is a pioneer in real-world data analysis of biologic therapies for psoriasis, as demonstrated in several of his prospective, multicenter studies. His focus also includes the gut-skin axis, autoimmune dermatoses, and health policy studies aimed at improving access to dermatological care. In recent years, he has expanded his work into emerging infectious diseases like monkeypox, integrating public health into clinical dermatology. His work is often collaborative, involving multi-disciplinary teams and cross-border research. Dr. Liang is especially committed to improving healthcare delivery systems in dermatology, with a unique emphasis on evidence-based treatment, quality of life metrics, and healthcare worker training. His future focus aims to further explore microbiome-immune interactions in skin disease and introduce AI-driven diagnostic support systems. His research portfolio aligns with global dermatological priorities, positioning him as a leader in innovation and care.

Publications – One-line Format with Emojis

  1.  Cutaneous and systemic improvements in psoriasis after biologics in real-world study – Scientific Reports, 2025

  2.  Gut microbiota and psoriasis: A systematic review – Eur J Pharmacol, 2025

  3.  Hereditary Angioedema in China: Awareness and Advocacy from Greater Bay to Global – Clin Exp Allergy, 2025

  4.  Healthcare workers’ monkeypox knowledge and confidence survey – World J Clin Cases, 2025

  5.  Reducing recurrence of Condyloma Acuminatum via lesional auto-transplantation – J Cosmetics, Dermatol Sci Appl, 2024

  6.  Atopic Dermatitis: From Bench to Bedside – Front Med, 2024

  7.  Ixekizumab safety in Chinese plaque psoriasis patients – 12-week observational study – Drug Saf, 2024

  8. Effectiveness of Ixekizumab in special area involvement psoriasis patients – Dermatol Ther (Heidelb), 2024

  9. Quality of life and predictors of complete skin clearance in psoriasis – Dermatology, 2023

  10. Ixekizumab safety and efficacy in Chinese psoriasis patients – Prospective real-world study – Adv Ther, 2023

Conclusion

Dr. Yan-Hua Liang is a highly accomplished clinician-scientist whose integrated focus on clinical excellence, academic mentorship, and research productivity positions him as a leading candidate for the Best Researcher Award. His commitment to real-world research, particularly in psoriasis and biologic therapy, is both impactful and timely.

Given his sustained contributions, ongoing innovative work, and national academic leadership, Dr. Liang exemplifies the qualities of a modern, translational researcher who is significantly advancing dermatology in China and beyond.